Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

Huscher, Dörte; Merkesdal, Sonja; Thiele, Kathi; Zeidler, Henning; Schneider, M; Zink, Angela

doi:10.1136/ard.2005.046367

Cited by 257 publications

(261 citation statements)

References 23 publications

Supporting

Mentioning

213

Contrasting

Unclassified

Order By: Relevance

“…Previously costeffectiveness models of biologicals assumed linear relationship between functional status (HAQ) and direct costs in PsA based on RA data [12][13]. Huscher et al [4] confirmed this relation of total costs based on a PsA study and our results pointed out the same with HAQ.…”

Section: Discussionsupporting

confidence: 84%

“…[14] Comparing our results with available data from other countries is challenging due to differences in inclusion criteria and study design. Huscher et al [4] reported about twofold higher total costs of PsA patients in working age (18-65 years) in Germany (mean 11 075 euros/patient/year in 2002), and the proportion of indirect cost was much higher there (71.5% vs. 52%). Considering only patients in working age (18-62 years) we still find lower total costs in Hungary (6 254 euros/year/patient, indirect costs: 56 %).…”

Section: Discussionmentioning

confidence: 99%

“…Huscher et al [4] also reported lower total costs and DMARD costs of PsA than RA but the rate of DMARD use was similar in the two conditions there (84% vs. 90%). [14] Comparing our results with available data from other countries is challenging due to differences in inclusion criteria and study design.…”

Section: Discussionmentioning

confidence: 99%

“…Javitz et al [3] described the burden of psoriasis and PsA in the USA on the 1997 basis but their method was not appropriate according to Ackermann's review. Huscher et al studied the costs of inflammatory rheumatic diseases in Germany on the 2002 basis but results from an economically developed country are not squarely relevant for all regions of Europe [4]. There are no data on costs of PsA neither from Hungary nor from countries with similar economic status, health care and insurance system (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

Brodszky

Bálint

Géher³

et al. 2009

Rheumatol Int

View full text Add to dashboard Cite

International audienceThe objectives of this study were to assess the costs of psoriatic arthritis (PsA) in Hungary and to identify key cost drivers among demographic and clinical variables and to compare cost-of-illness of PsA and rheumatoid arthritis (RA). Cross-sectional retrospective survey of 183 consecutive patients from eight rheumatology centres was conducted. Mean direct medical, direct non medical, indirect and total costs were 1,876, 794, 2,904 and 5,574 euros/patient/year, respectively. Total costs were in significant linear relationship with health assessment questionnaire score and psoriatic area severity index. Costs of RA were higher in all domains than of PsA. Our study was the first from the Eastern European region that provides cost-of-illness data on PsA. Our study revealed that functional status and severity of skin symptoms were the key cost drivers. The costs of PsA in Hungary were lower than in the high-income European countries

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

Brodszky

Bálint

Géher³

et al. 2009

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…The high prevalence of AS and other SpA implicates a substantial impact on health and quality of life for individual patients and an economic burden for society (5)(6)(7)(8).…”

mentioning

confidence: 99%

The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort

Rudwaleit¹,

Haibel²,

Baraliakos³

et al. 2009

Arthritis & Rheumatism

649

406

View full text Add to dashboard Cite

Objective. Ankylosing spondylitis (AS) is diagnosed late, because radiographs of the sacroiliac joints often do not show definite sacroiliitis at the time of disease onset. The aim of this study was to investigate whether patients without definite radiographically defined sacroiliitis, referred to as nonradiographic axial spondylarthritis (SpA), are different from patients with AS with regard to clinical manifestations and disease activity measures. Moreover, we sought to identify determinants of the development of radiographic sacroiliitis.Methods. In a cross-sectional analysis of 462 patients, we compared 226 patients with nonradiographic axial SpA (symptom duration <5 years) and 236 patients with AS (symptom duration <10 years) who are participants in the German Spondyloarthritis Inception Cohort. Radiographs of the sacroiliac joints and the spine were assessed by 2 readers in a blinded manner. Logistic regression analysis was applied to identify parameters associated with structural damage.Results. The 2 groups did not differ in the frequency of HLA-B27 positivity, inflammatory back pain, arthritis, enthesitis, and uveitis and had similar levels of disease activity, using measures such as the Bath Ankylosing Spondylitis Disease Activity Index. In both groups, HLA-B27 positivity determined the age at disease onset. Conclusion. Clinical manifestations and disease activity measures are highly comparable between patients with early nonradiographic axial SpA and those with early AS, suggesting that these 2 entities are part of the same disease. Male sex and an elevated CRP level are associated with structural damage on radiographs, whereas HLA-B27 positivity determines the age at disease onset.

show abstract

Cost‐of‐illness studies in systemic lupus erythematosus: A systematic review

Zhu¹,

Tam²,

Li³

2011

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To summarize the state of knowledge regarding the economic burden of systemic lupus erythematosus (SLE) and to evaluate the quality of cost-of-illness (COI) studies conducted to date. Conclusion. There is a substantial economic burden, in terms of health care resource utilization, associated with SLE, as well as losses of productivity due to work capacity impairment. The cost estimates in this review should be used with caution due to significant discrepancies in methodologies across studies. Future studies should address several methodologic considerations in order to measure the true costs related to SLE. Incidence-based COI studies are needed to evaluate the lifetime costs of SLE.

show abstract

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

Abstract: The costs of illness are high in all four diseases, with a strong effect of functional status on total costs. Indirect costs differ by the factor 3, based on whether the HCA or the FCA is used.

Cited by 257 publications

References 23 publications

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort

Cost‐of‐illness studies in systemic lupus erythematosus: A systematic review

Contact Info

Product

Resources

About